Medartis Holding AG (CH:MED)
:MED
Want to see CH:MED full AI Analyst Report?
Top Page
Medartis Holding AG
(MED)
Select Model
Select Model
Rating:51Neutral
Price Target:
CHF73.00
▼(-17.23% Downside)
Action:ReiteratedDate:03/23/26
The score is held back primarily by uneven profitability alongside rising leverage and weaker 2025 free cash flow, despite solid revenue growth and improving operating cash flow. Technical indicators also remain bearish with the stock trading below major moving averages. Valuation is a further headwind due to a negative P/E and no dividend support.
Positive Factors
Revenue Growth
Consistent top-line growth (mid-single to mid-teens historically, ~19.8% reported) indicates expanding procedure adoption and stronger market penetration. Durable revenue expansion supports reinvestment in product development, surgeon training and geographic roll‑out that drive recurring implant demand.
Negative Factors
Rising Leverage
Material increase in debt over two years materially raises financial risk and reduces strategic flexibility. Higher leverage increases interest and covenant sensitivity, leaving the company more exposed to margin swings and potentially constraining investments or M&A absent sustained cash flow improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent top-line growth (mid-single to mid-teens historically, ~19.8% reported) indicates expanding procedure adoption and stronger market penetration. Durable revenue expansion supports reinvestment in product development, surgeon training and geographic roll‑out that drive recurring implant demand.
Read all positive factors
Medartis Holding AG (MED) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.05B
Dividend YieldN/A
Average Volume (3M)6.38K
Price to Earnings (P/E)28.0
Beta (1Y)0.87
Revenue Growth19.76%
EPS Growth150.73%
CountryCH
Employees816
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.67
Shares Outstanding13,632,551
10 Day Avg. Volume7,172
30 Day Avg. Volume6,381
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)3.97
Price to Sales (P/S)4.07
P/FCF Ratio117.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF87.00Price Target Upside-1.36% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.49
Revenue Forecast (FY)CHF326.26M
Medartis Holding AG Business Overview & Revenue Model
Company Description
Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the...
How the Company Makes Money
Medartis makes money primarily by selling osteosynthesis product systems—implant plates, screws, and associated surgical instruments—used in trauma and orthopedic procedures. Revenue is generated when hospitals, surgical centers, and distributors ...
Medartis Holding AG Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 269.26M | 224.83M | 212.01M | 182.82M | 159.88M |
| Gross Profit | 204.33M | 178.68M | 167.57M | 135.39M | 121.57M |
| EBITDA | 45.72M | 30.18M | 24.69M | 15.64M | 26.10M |
| Net Income | 8.35M | 3.53M | 619.00K | -5.78M | 6.84M |
Balance Sheet | |||||
| Total Assets | 559.92M | 459.96M | 349.53M | 327.89M | 298.18M |
| Cash, Cash Equivalents and Short-Term Investments | 32.97M | 138.69M | 25.20M | 20.60M | 82.64M |
| Total Debt | 157.72M | 121.23M | 27.39M | 27.96M | 24.07M |
| Total Liabilities | 284.05M | 190.31M | 94.58M | 90.11M | 74.18M |
| Stockholders Equity | 275.87M | 269.65M | 254.96M | 237.78M | 224.00M |
Cash Flow | |||||
| Free Cash Flow | 9.34M | 21.00M | 5.05M | -22.72M | 10.57M |
| Operating Cash Flow | 34.82M | 28.17M | 19.96M | -3.93M | 20.95M |
| Investing Cash Flow | -146.26M | -19.06M | -37.83M | -52.91M | -15.87M |
| Financing Cash Flow | 6.83M | 100.58M | 23.21M | -3.90M | -4.78M |
Medartis Holding AG Technical Analysis
Neutral
88.20
Price Trends
84.68
Negative
86.15
Negative
84.60
Negative
Market Momentum
-1.35
Negative
48.55
Neutral
21.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Neutral. The current price of 88.2 is above the 20-day moving average (MA) of 79.72, above the 50-day MA of 84.68, and above the 200-day MA of 84.60, indicating a neutral trend. The MACD of -1.35 indicates Negative momentum. The RSI at 48.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:MED.
Medartis Holding AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF669.55M | 6.84 | ― | ― | 11.43% | -48.80% | |
68 Neutral | CHF10.27B | 17.11 | ― | 2.14% | 3.79% | -7.84% | |
64 Neutral | CHF2.74B | 23.81 | 23.76% | 0.45% | 13.93% | 28.92% | |
62 Neutral | CHF3.70B | 7.90 | 15.79% | 0.51% | 2.57% | 4.31% | |
61 Neutral | CHF1.69B | -3.17 | 4.57% | 2.31% | -5.54% | -264.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | CHF1.05B | 27.98 | ― | ― | 19.76% | 150.73% |
* Healthcare Sector Average
CH:MED
Medartis Holding AG
76.90
4.30
5.92%
CH:SOON
Sonova Holding AG
178.50
-79.12
-30.71%
CH:BSLN
Basilea Pharmaceutica
54.50
10.10
22.75%
CH:MOVE
Medacta Group SA
137.20
-0.74
-0.53%
CH:SFZN
Siegfried Holding AG
82.05
-15.05
-15.50%
CH:TECN
Tecan Group AG
131.80
-27.11
-17.06%
Medartis Holding AG Corporate Events
Medartis Investors Strongly Approve Board Proposals and Governance at 2026 AGM
Apr 23, 2026
Medartis shareholders strongly backed the Board of Directors at the 2026 annual general meeting, with 77.4% of share capital represented and all proposals approved by majorities above 90.9%. Seven board members were re-elected, Yang Xu joined the ...
Medartis Extends Growth Run With Double-Digit Sales Increase and Strategic Acquisitions
Mar 17, 2026
Medartis reported 2025 total sales of CHF 269.3 million, with core sales up 15.7% organically at constant exchange rates and double-digit growth across all regions, led by EMEA, while maintaining a core EBITDA margin of 18.4% despite currency head...
Medartis schedules March 2026 conference to unveil 2025 results and 2026 outlook
Feb 10, 2026
Medartis Holding AG will present its 2025 annual results and provide an outlook for 2026 at a press and investor conference to be held at its Basel headquarters on 17 March 2026, with CEO Matthias Schupp and newly appointed CFO Peter Hackel as spe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.